171 related articles for article (PubMed ID: 38612869)
21. Critical role of cyclin D1 nuclear import in cardiomyocyte proliferation.
Tamamori-Adachi M; Ito H; Sumrejkanchanakij P; Adachi S; Hiroe M; Shimizu M; Kawauchi J; Sunamori M; Marumo F; Kitajima S; Ikeda MA
Circ Res; 2003 Jan; 92(1):e12-9. PubMed ID: 12522130
[TBL] [Abstract][Full Text] [Related]
22. PLA2G10 facilitates the cell-cycle progression of soft tissue leiomyosarcoma cells at least by elevating cyclin E1/CDK2 expression.
Tan G; Zhang GY; Xu J; Kang CW; Yan ZK; Lei M; Pu XB; Dong CC
Biochem Biophys Res Commun; 2020 Jun; 527(2):525-531. PubMed ID: 32423798
[TBL] [Abstract][Full Text] [Related]
23. Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway.
Le XF; Bedrosian I; Mao W; Murray M; Lu Z; Keyomarsi K; Lee MH; Zhao J; Bast RC
Cell Cycle; 2006 Aug; 5(15):1654-61. PubMed ID: 16861913
[TBL] [Abstract][Full Text] [Related]
24. Construction of a cyclin D1-Cdk2 fusion protein to model the biological functions of cyclin D1-Cdk2 complexes.
Chytil A; Waltner-Law M; West R; Friedman D; Aakre M; Barker D; Law B
J Biol Chem; 2004 Nov; 279(46):47688-98. PubMed ID: 15355984
[TBL] [Abstract][Full Text] [Related]
25. Expression of G1 phase regulators in MG-63 osteosarcoma cell line.
Merli M; Benassi MS; Gamberi G; Ragazzini P; Sollazzo MR; Molendini L; Magagnoli G; Ferrari C; Maltarello MC; Picci P
Int J Oncol; 1999 Jun; 14(6):1117-21. PubMed ID: 10339667
[TBL] [Abstract][Full Text] [Related]
26. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2.
Kitagawa M; Higashi H; Jung HK; Suzuki-Takahashi I; Ikeda M; Tamai K; Kato J; Segawa K; Yoshida E; Nishimura S; Taya Y
EMBO J; 1996 Dec; 15(24):7060-9. PubMed ID: 9003781
[TBL] [Abstract][Full Text] [Related]
27. Alterations of pRb1-cyclin D1-cdk4/6-p16(INK4A) pathway in endometrial carcinogenesis.
Semczuk A; Jakowicki JA
Cancer Lett; 2004 Jan; 203(1):1-12. PubMed ID: 14670612
[TBL] [Abstract][Full Text] [Related]
28. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity.
Lukas J; Bartkova J; Rohde M; Strauss M; Bartek J
Mol Cell Biol; 1995 May; 15(5):2600-11. PubMed ID: 7739541
[TBL] [Abstract][Full Text] [Related]
29. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points.
Mateyak MK; Obaya AJ; Sedivy JM
Mol Cell Biol; 1999 Jul; 19(7):4672-83. PubMed ID: 10373516
[TBL] [Abstract][Full Text] [Related]
30. Biochemical characterizations reveal different properties between CDK4/cyclin D1 and CDK2/cyclin A.
Kim DM; Yang K; Yang BS
Exp Mol Med; 2003 Oct; 35(5):421-30. PubMed ID: 14646596
[TBL] [Abstract][Full Text] [Related]
31. Inducible expression of cyclin D1 in T-47D human breast cancer cells is sufficient for Cdk2 activation and pRB hyperphosphorylation.
Musgrove EA; Sarcevic B; Sutherland RL
J Cell Biochem; 1996 Mar; 60(3):363-78. PubMed ID: 8867812
[TBL] [Abstract][Full Text] [Related]
32. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry.
Prall OW; Rogan EM; Musgrove EA; Watts CK; Sutherland RL
Mol Cell Biol; 1998 Aug; 18(8):4499-508. PubMed ID: 9671459
[TBL] [Abstract][Full Text] [Related]
33. Effects of cyclin D1 overexpression on G1 progression-related events.
Imoto M; Doki Y; Jiang W; Han EK; Weinstein IB
Exp Cell Res; 1997 Oct; 236(1):173-80. PubMed ID: 9344597
[TBL] [Abstract][Full Text] [Related]
34. CaMK-II inhibition reduces cyclin D1 levels and enhances the association of p27kip1 with Cdk2 to cause G1 arrest in NIH 3T3 cells.
Morris TA; DeLorenzo RJ; Tombes RM
Exp Cell Res; 1998 May; 240(2):218-27. PubMed ID: 9596994
[TBL] [Abstract][Full Text] [Related]
35. Disruption of the actin cytoskeleton leads to inhibition of mitogen-induced cyclin E expression, Cdk2 phosphorylation, and nuclear accumulation of the retinoblastoma protein-related p107 protein.
Reshetnikova G; Barkan R; Popov B; Nikolsky N; Chang LS
Exp Cell Res; 2000 Aug; 259(1):35-53. PubMed ID: 10942577
[TBL] [Abstract][Full Text] [Related]
36. miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6.
Xia B; Yang S; Liu T; Lou G
Mol Cancer; 2015 Mar; 14():57. PubMed ID: 25889927
[TBL] [Abstract][Full Text] [Related]
37. Expression of cyclin E renders cyclin D-CDK4 dispensable for inactivation of the retinoblastoma tumor suppressor protein, activation of E2F, and G1-S phase progression.
Keenan SM; Lents NH; Baldassare JJ
J Biol Chem; 2004 Feb; 279(7):5387-96. PubMed ID: 14645251
[TBL] [Abstract][Full Text] [Related]
38. Increased expression of the P27KIP1 protein in human esophageal cancer cell lines that over-express cyclin D1.
Doki Y; Imoto M; Han EK; Sgambato A; Weinstein IB
Carcinogenesis; 1997 Jun; 18(6):1139-48. PubMed ID: 9214595
[TBL] [Abstract][Full Text] [Related]
39. CDK2 is a target for retinoic acid-mediated growth inhibition in MCF-7 human breast cancer cells.
Teixeira C; Pratt MA
Mol Endocrinol; 1997 Aug; 11(9):1191-202. PubMed ID: 9259311
[TBL] [Abstract][Full Text] [Related]
40. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.
Whittaker SR; Walton MI; Garrett MD; Workman P
Cancer Res; 2004 Jan; 64(1):262-72. PubMed ID: 14729633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
